Development of In vitro endothelialized drug-eluting stent using human peripheral blood-derived endothelial progenitor cells.

PURPOSE We propose in vitro endothelialization of drug-eluting stents (DES) to overcome late stent thrombosis by directly introducing late-outgrowth human endothelial progenitor cells (EPCs) at the target site utilizing abluminal DES. MATERIALS AND METHODS Isolated EPCs were confirmed as late-outgrowth EPCs by flow cytometric analysis. Abluminally paclitaxel-loaded stents were seeded with different cell concentrations and durations to determine optimal seeding conditions, in both uncrimped and crimped configurations. The seeding yield was determined by evaluating the percent coverage of the stent struts' area. The EPC-seeded DES were exposed to arterial shear stress to evaluate the effect of high shear stress on EPCs. To investigate how much Paclitaxel elutes during the seeding procedure, a pharmacokinetic analysis was performed. Finally, to validate the proof-of-concept, EPC-seeded DES were placed on a fibrin matrix with and without smooth muscles cells (SMCs) and cultured for 3 days under perfusion. RESULTS The seeding procedure resulted in 47% and 26% coverage of the stent surface in uncrimped and crimped conditions, respectively. After the optimal seeding, almost 99% of drug was still available. When EPC-seeded DES were placed on a fibrin matrix and cultured for 3 days, the EPCs confluently covered the stent surface and spread to the surrounding fibrin gel. When EPC-seeded DES were placed on SMCs-containing fibrin layers, cells in contact with the struts died. CONCLUSIONS EPCs can be successfully seeded onto DES without losing drug-eluting capability and EPCs exhibit sufficient proliferative ability. EPC-seeded DES may combine early re-endothelialization ability with the anti-restenotic effectiveness of DES.